NCT04145583View on ClinicalTrials.gov

A Study Evaluating Drug-Drug Interaction (DDI) Between HSK3486 Injectable Emulsion and Voriconazole Tablets

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

December 14, 2019

Primary Completion Date

January 6, 2020

Study Completion Date

May 9, 2020

Conditions
AnesthesiaSedation
Interventions
DRUG

HSK3486

Sequence 1: Intravenously infuse 0.4 mg/kg HSK3486 in the morning on an empty stomach. Complete infusion within 1 min.

DRUG

voriconazole +HSK3486

Sequence 2: voriconazole：Day 1,400mg，BID；Day 2--Day 6,200mg，BID；200 mg of voriconazole were taken orally in the morning on an empty stomach of Day 7; followed by 1 min intravenous infusion of 0.4 mg/kg HSK3486 30 min later.

Trial Locations (1)

Unknown

the First Affilicated Hospital of Soochow University, Suzhou

All Listed Sponsors
lead

Sichuan Haisco Pharmaceutical Group Co., Ltd

INDUSTRY

NCT04145583 - A Study Evaluating Drug-Drug Interaction (DDI) Between HSK3486 Injectable Emulsion and Voriconazole Tablets | Biotech Hunter | Biotech Hunter